Abstract
Fourteen evaluable patients with advanced ovarian cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicity was granulocytopenia with 50% of patients having granulocyte counts of less than 1,000/microliter. Based on this study and one other previously published trial, fludarabine phosphate does not appear to be an active agent for patients with refractory ovarian cancer.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Agranulocytosis / chemically induced
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Arabinonucleotides / therapeutic use*
-
Drug Evaluation
-
Female
-
Humans
-
Infusions, Intravenous
-
Middle Aged
-
Ovarian Neoplasms / drug therapy*
-
Vidarabine Phosphate / adverse effects
-
Vidarabine Phosphate / analogs & derivatives
-
Vidarabine Phosphate / therapeutic use*
Substances
-
Antineoplastic Agents
-
Arabinonucleotides
-
Vidarabine Phosphate
-
fludarabine phosphate